Aims In patients at high risk of heart failure following myocardial infarction (MI) as a result of
residual left ventricular systolic dysfunction (LVSD), the angiotensin receptor neprilysin …

Background: Patients with left ventricular (LV) systolic dysfunction after myocardial infarction
are at a high risk of developing heart failure. The addition of neprilysin inhibition to renin …

Angiotensin receptor neprilysin inhibitors (ARNI), a new therapeutic class of agents acting
on the renin angiotensin aldosterone system (RAAS) and neutral endopeptidase system has …

Abstract Purpose of Review The goal of this article is to review potential expanded
indications for neprilysin inhibitors. This article reviews the rationale and design for ongoing …

Inhibition of neurohumoural pathways such as the renin angiotensin aldosterone and
sympathetic nervous systems is central to the understanding and treatment of heart failure …

Background The angiotensin‐receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was
shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of …

One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …

Background Angiotensin receptor neprilysin inhibitor (ARNI) sacubitril‐valsartan has been
recommended as one of the first‐line therapies in heart failure with reduced ejection fraction …

Angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy improves the prognosis of
heart failure patients. However, the mechanisms remain unclear. This study investigated the …

The addition of a neprilysin inhibitor to a renin–angiotensin system (RAS) antagonist, using
the combination of sacubitril and valsartan, was shown to reduce morbidity and mortality in …